Update shared on 04 Nov 2025
Narrative Update on Piramal Enterprises Analyst Price Target
Analysts have kept their price target for Piramal Enterprises unchanged at ₹1,269, citing little change in key outlook factors such as the discount rate, revenue growth, and profit margin.
What's in the News
- Piramal Pharma Solutions, part of Piramal Pharma Ltd., signed a memorandum of understanding with IntoCell Inc. to explore collaborations in antibody drug conjugate (ADC) development and license proprietary drug-linker technologies. This agreement broadens Piramal's bioconjugation capabilities and service offerings. (Client Announcements)
- Piramal will gain access to IntoCell's proprietary drug-linker technologies, such as the OHPAS linker, Duocarmycin based OHPAS-payload, and Nexatecan based GGFG-payload, further strengthening its ADCelerate™ platform. (Client Announcements)
- Mrs. Upma Goel, Chief Financial Officer and Key Managerial Personnel, has submitted her resignation. Her last working day will be at the close of business on September 30, 2025. (Executive Changes, CFO)
Valuation Changes
- Consensus Analyst Price Target remains unchanged at ₹1,269.
- The discount rate has risen slightly, moving from 14.20% to 14.22%.
- Revenue growth is effectively flat, holding steady at approximately 10.95%.
- Net profit margin shows no meaningful change, staying at 34.88%.
- The future P/E ratio has edged up marginally from 14.20x to 14.20x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.